TP53 and acute myeloid leukemia: NPM1 mutations are identified in 5.4% of patients without concurrent “secondary-type” or TP53 mutations [8,30,52], suggesting that there is a non-random pattern of co-mutations with mutual exclusivity between TP53 and NPM1 mutations in t-AML.